These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22497712)

  • 1. Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.
    Davidson YS; Robinson AC; Hu Q; Mishra M; Baborie A; Jaros E; Perry RH; Cairns NJ; Richardson A; Gerhard A; Neary D; Snowden JS; Bigio EH; Mann DM
    Neuropathol Appl Neurobiol; 2013 Feb; 39(2):157-65. PubMed ID: 22497712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
    Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
    Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
    Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
    Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.
    Deng Q; Holler CJ; Taylor G; Hudson KF; Watkins W; Gearing M; Ito D; Murray ME; Dickson DW; Seyfried NT; Kukar T
    J Neurosci; 2014 Jun; 34(23):7802-13. PubMed ID: 24899704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis.
    Mackenzie IR; Neumann M
    Brain Res; 2012 Jun; 1462():40-3. PubMed ID: 22261247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS.
    Gittings LM; Foti SC; Benson BC; Gami-Patel P; Isaacs AM; Lashley T
    Acta Neuropathol Commun; 2019 Feb; 7(1):18. PubMed ID: 30755280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transportin1: a marker of FTLD-FUS.
    Brelstaff J; Lashley T; Holton JL; Lees AJ; Rossor MN; Bandopadhyay R; Revesz T
    Acta Neuropathol; 2011 Nov; 122(5):591-600. PubMed ID: 21847626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An autopsy case of frontotemporal lobar degeneration with the appearance of fused in sarcoma inclusions (basophilic inclusion body disease) clinically presenting corticobasal syndrome.
    Matsumoto A; Suzuki H; Fukatsu R; Shimizu H; Suzuki Y; Hisanaga K
    Neuropathology; 2016 Feb; 36(1):77-87. PubMed ID: 26227957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.
    A Armstrong R
    Folia Neuropathol; 2017; 55(3):185-192. PubMed ID: 28984110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.
    Troakes C; Hortobágyi T; Vance C; Al-Sarraj S; Rogelj B; Shaw CE
    Neuropathol Appl Neurobiol; 2013 Aug; 39(5):553-61. PubMed ID: 22934812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The presence of heterogeneous nuclear ribonucleoproteins in frontotemporal lobar degeneration with FUS-positive inclusions.
    Gami-Patel P; Bandopadhyay R; Brelstaff J; Revesz T; Lashley T
    Neurobiol Aging; 2016 Oct; 46():192-203. PubMed ID: 27500866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS.
    Suárez-Calvet M; Neumann M; Arzberger T; Abou-Ajram C; Funk E; Hartmann H; Edbauer D; Kremmer E; Göbl C; Resch M; Bourgeois B; Madl T; Reber S; Jutzi D; Ruepp MD; Mackenzie IR; Ansorge O; Dormann D; Haass C
    Acta Neuropathol; 2016 Apr; 131(4):587-604. PubMed ID: 26895297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAF15 amyloid filaments in frontotemporal lobar degeneration.
    Tetter S; Arseni D; Murzin AG; Buhidma Y; Peak-Chew SY; Garringer HJ; Newell KL; Vidal R; Apostolova LG; Lashley T; Ghetti B; Ryskeldi-Falcon B
    Nature; 2024 Jan; 625(7994):345-351. PubMed ID: 38057661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological features of FTLD-FUS in a Japanese population: analyses of nine cases.
    Kobayashi Z; Kawakami I; Arai T; Yokota O; Tsuchiya K; Kondo H; Shimomura Y; Haga C; Aoki N; Hasegawa M; Hosokawa M; Oshima K; Niizato K; Ishizu H; Terada S; Onaya M; Ikeda M; Oyanagi K; Nakano I; Murayama S; Akiyama H; Mizusawa H
    J Neurol Sci; 2013 Dec; 335(1-2):89-95. PubMed ID: 24050818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
    Neumann M
    Rev Neurol (Paris); 2013 Oct; 169(10):793-8. PubMed ID: 24011641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in wasteosomes (corpora amylacea) in frontotemporal lobar degeneration with specific detection of tau, TDP-43 and FUS pathology.
    Alsina R; Riba M; Pérez-Millan A; Borrego-Écija S; Aldecoa I; Romera C; Balasa M; Antonell A; Lladó A; Compta Y; Del Valle J; Sánchez-Valle R; Pelegrí C; Molina-Porcel L; Vilaplana J
    Acta Neuropathol Commun; 2024 Jun; 12(1):97. PubMed ID: 38879502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FUS pathology in basophilic inclusion body disease.
    Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
    Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
    Seelaar H; Klijnsma KY; de Koning I; van der Lugt A; Chiu WZ; Azmani A; Rozemuller AJ; van Swieten JC
    J Neurol; 2010 May; 257(5):747-53. PubMed ID: 19946779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration.
    Kawakami I; Kobayashi Z; Arai T; Yokota O; Nonaka T; Aoki N; Niizato K; Oshima K; Higashi S; Katsuse O; Hosokawa M; Hasegawa M; Akiyama H
    Acta Neuropathol Commun; 2016 Apr; 4():36. PubMed ID: 27044537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
    Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
    J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.